Skip to Content

Cassava Sciences Inc SAVA

Morningstar Rating
$10.18 +0.61 (6.37%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

SAVA is trading at a 879% premium.
Price
$10.23
Fair Value
$53.17
Uncertainty
Extreme
1-Star Price
$357.96
5-Star Price
$4.73
Economic Moat
Ghkz
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SAVA is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$9.57
Day Range
$9.4710.73
52-Week Range
$8.7932.10
Bid/Ask
$10.00 / $10.30
Market Cap
$488.40 Mil
Volume/Avg
1,019 / 1.8 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer’s disease dementia.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
29

Comparables

Valuation

Metric
SAVA
MLYS
VKTX
Price/Earnings (Normalized)
Price/Book Value
5.602.065.91
Price/Sales
Price/Cash Flow
Price/Earnings
SAVA
MLYS
VKTX

Financial Strength

Metric
SAVA
MLYS
VKTX
Quick Ratio
1.6217.6329.38
Current Ratio
1.7418.0629.48
Interest Coverage
Quick Ratio
SAVA
MLYS
VKTX

Profitability

Metric
SAVA
MLYS
VKTX
Return on Assets (Normalized)
−23.26%−28.59%−15.98%
Return on Equity (Normalized)
−27.60%−29.81%−16.71%
Return on Invested Capital (Normalized)
−32.61%−34.85%−21.42%
Return on Assets
SAVA
MLYS
VKTX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
QgzfywlvjbXhx$579.2 Bil
Vertex Pharmaceuticals Inc
VRTX
JpzwyjtrRbctkx$126.0 Bil
Regeneron Pharmaceuticals Inc
REGN
WrjksfppvTqwbgc$117.6 Bil
Moderna Inc
MRNA
LxgyhvltgNqrpf$46.5 Bil
Alnylam Pharmaceuticals Inc
ALNY
FzdnsltcfXfqkwrc$29.9 Bil
argenx SE ADR
ARGX
LnzlrrmxSpqn$27.7 Bil
BioNTech SE ADR
BNTX
ZcfdfzqxRwkn$20.8 Bil
Biomarin Pharmaceutical Inc
BMRN
TghvxgqlfRkhpbs$15.8 Bil
United Therapeutics Corp
UTHR
XzctykzJfgq$14.6 Bil
Incyte Corp
INCY
FzjjftsHxvkrx$12.9 Bil

Sponsor Center